HORMONE / FDA APPROVED
PT-141 (Bremelanotide / Vyleesi)
Subcutaneous injection
Overview
A synthetic cyclic heptapeptide melanocortin receptor agonist that activates MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141 works centrally through hypothalamic melanocortin pathways that modulate sexual arousal and desire.
Mechanism of Action
It is a metabolite of Melanotan II without significant melanogenic activity.
​Research Summary & Key Findings
FDA-approved in 2019 (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. RECONNECT trials showed statistically significant increases in sexual desire and reduction in distress. First centrally-acting treatment for female sexual dysfunction.
Clinical Status
FDA APPROVED
PT-141 (Bremelanotide / Vyleesi) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
Subcutaneous injection (weekly)
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.